Sichuan Hebang Biotechnology Corporation Limited
603077.SS · SHH
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | CN¥8,547,477 | CN¥8,824,108 | CN¥13,038,948 | CN¥9,987,354 |
| % Growth | -3.1% | -32.3% | 30.6% | – |
| Cost of Goods Sold | CN¥8,010,296 | CN¥6,823,381 | CN¥7,492,217 | CN¥5,873,867 |
| Gross Profit | CN¥537,181 | CN¥2,000,727 | CN¥5,546,731 | CN¥4,113,486 |
| % Margin | 6.3% | 22.7% | 42.5% | 41.2% |
| R&D Expenses | CN¥30,626 | CN¥47,347 | CN¥67,934 | CN¥33,313 |
| G&A Expenses | CN¥402,317 | CN¥386,731 | CN¥803,609 | CN¥281,520 |
| SG&A Expenses | CN¥481,568 | CN¥446,294 | CN¥856,092 | CN¥333,607 |
| Sales & Mktg Exp. | CN¥79,251 | CN¥59,562 | CN¥52,483 | CN¥52,088 |
| Other Operating Expenses | CN¥86,779 | -CN¥34,706 | CN¥141,548 | CN¥155,490 |
| Operating Expenses | CN¥598,973 | CN¥458,935 | CN¥1,065,573 | CN¥522,410 |
| Operating Income | -CN¥61,793 | CN¥1,541,792 | CN¥4,481,157 | CN¥3,591,076 |
| % Margin | -0.7% | 17.5% | 34.4% | 36% |
| Other Income/Exp. Net | -CN¥3,891 | -CN¥5,827 | -CN¥2,595 | -CN¥12,696 |
| Pre-Tax Income | -CN¥65,684 | CN¥1,535,966 | CN¥4,478,562 | CN¥3,578,380 |
| Tax Expense | CN¥5,061 | CN¥257,266 | CN¥668,323 | CN¥551,879 |
| Net Income | CN¥31,465 | CN¥1,283,244 | CN¥3,806,809 | CN¥3,018,471 |
| % Margin | 0.4% | 14.5% | 29.2% | 30.2% |
| EPS | 0.004 | 0.147 | 0.438 | 0.358 |
| % Growth | -97.4% | -66.3% | 22.3% | – |
| EPS Diluted | 0.004 | 0.147 | 0.438 | 0.358 |
| Weighted Avg Shares Out | 8,280,180 | 8,705,861 | 8,697,302 | 8,436,195 |
| Weighted Avg Shares Out Dil | 8,503,969 | 8,705,861 | 8,697,302 | 8,436,195 |
| Supplemental Information | – | – | – | – |
| Interest Income | CN¥47,050 | CN¥60,351 | CN¥22,689 | CN¥9,358 |
| Interest Expense | CN¥66,882 | CN¥28,639 | CN¥52,033 | CN¥79,057 |
| Depreciation & Amortization | CN¥974,685 | CN¥988,231 | CN¥914,519 | CN¥631,019 |
| EBITDA | CN¥924,255 | CN¥2,409,894 | CN¥5,400,098 | CN¥4,281,552 |
| % Margin | 10.8% | 27.3% | 41.4% | 42.9% |